8-KFiled Aug 12, 8:00 PM ET
Serina Therapeutics Reports Q2 2026 Quarterly Results
$SER · Serina Therapeutics, Inc.Research Summary
AI-generated summary of this SEC filing
Serina Therapeutics Reports Q2 2026 Quarterly Results
What Happened
Serina Therapeutics, Inc. announced on August 13, 2026 that it issued a press release reporting its financial results for the quarter ended June 30, 2026. The company furnished that press release as an exhibit to its Form 8-K filed the same day.
Key Details
- Item reported: 2.02 (Results of Operations and Financial Condition) — press release announcing quarterly financial results.
- Filing date: August 13, 2026; quarter covered: ended June 30, 2026.
- Exhibits furnished: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File / Inline XBRL).
- Form 8-K signed by CEO Steve Ledger on August 13, 2026.
Why It Matters
This 8-K formally notifies investors that Serina has publicly released its latest quarterly financial results and related disclosures. Investors should review the furnished press release (Exhibit 99.1) and the company's filings for the specific financial figures, operational updates, and any commentary or guidance the company provided.